Cardiovascular studies of phenylpropanolamine

Area of Science:

• Pharmacology
• Cardiovascular Physiology

Background:

• Phenylpropanolamine (PPA) is a common ingredient in over-the-counter medications for appetite control and cold remedies.
• Concerns exist regarding PPA's impact on the human cardiovascular system.

Purpose of the Study:

• To investigate the cardiovascular effects of phenylpropanolamine in both anesthetized and unanesthetized dogs.
• To assess dose-dependency and potential tachyphylaxis of PPA's cardiovascular actions.

Main Methods:

• Cardiovascular parameters (blood pressure, heart rate, left ventricular force) were measured in beagle dogs.
• PPA was administered orally and intravenously at various doses in both conscious and anesthetized states.
• Repeated dose administration and effects of PPA in conjunction with norepinephrine were studied.

Main Results:

• Oral PPA induced dose-dependent increases in blood pressure and decreases in heart rate in conscious dogs.
• Repeated oral doses showed diminished effects (tachyphylaxis), which resolved after 24 hours.
• Anesthetized dogs showed complex responses, with low doses increasing heart rate and blood pressure, while higher doses had lesser effects.
• PPA pre-administration reduced the cardiovascular response to subsequent PPA doses and potentiated the pressor response to norepinephrine.

Conclusions:

• Phenylpropanolamine exerts significant, dose-dependent cardiovascular effects in dogs, including hypertension and bradycardia.
• Tachyphylaxis to PPA's cardiovascular effects can develop with repeated dosing.
• PPA may alter cardiovascular responses to other sympathomimetic agents like norepinephrine.